Do you want to read an article? Please log in or register.
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, A Highly Selective ALK Inhibitor, in Healthy Subjects
Lung, Respiratory and Thoracic CancerLymphoma
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G
doi: 10.1016/j.lungcan.2020.05.018.
Lymphoma
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
Oncotarget.
Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK
doi: 10.18632/oncotarget.25154.
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
Lung Cancer.
Breadner D, Blanchette P, Shanmuganathan S, Boldt RG, Raphael J
doi: 10.1016/j.lungcan.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials
J Thorac Oncol.
Noé J, Lovejoy A, Ignatius Ou SH, Yaung SJ, Bordogna W, Klass DM, Cummings CA, Shaw AT
doi: 10.1016/j.jtho.2019.10.015.
Further Publications
Clinical implications of food-drug interactions with small-molecule kinase inhibitors
Lancet Oncol.
Veerman GDM, Hussaarts KGAM, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ
doi: 10.1016/S1470-2045(20)30069-3.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Multiple Myeloma (MM)
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
Clin Pharmacokinet.
Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K
doi: 10.1007/s40262-017-0526-4.
Lung, Respiratory and Thoracic CancerLymphoma
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small-Cell Lung Cancer - A Multicenter Retrospective Study
J Thorac Oncol.
Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N
doi: 10.1016/j.jtho.2016.07.022.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study
J Thorac Oncol.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT
doi: 10.1016/j.jtho.2019.03.007.